Indication
Osteoporosis in male patient
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures. Read more about Osteoporosis in male patient
63 drugs 52 manufacturers
Drugs that treat it
Common Osteoporosis in male patient therapies.
TERIPARATIDE
ALENDRONATE SODIUM
ALENDRONATE SODIUM
RISEDRONATE SODIUM
RECLAST (zoledronic acid in mannitol and water for injection)
TERIPARATIDE
ALENDRONATE SODIUM
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonOsteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures.
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy.
Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of -2.5 or lower at the spine or hip, carrying significant morbidity and higher post-fracture mortality rates compared to female counterparts.
- nih.gov
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures
- nih.gov
Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying...
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy
- nih.gov
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy
- oup.com
In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying...
- nih.gov
Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of −2.5 or lower at the spine or hip, carrying significant morbidity and higher post-fracture mortality rates compared to female counterparts
Personalize your experience
Follow Osteoporosis in male patient and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.